CYTOKINETICS, INCORPORATED (CYTK) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 27.36M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 248.20M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 1.17B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.92B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $27.36M | $248.20M | (m) | $1.17B | $1.92B | (m) |
| 2026-03-31 | (m) | (m) | $44.81M | $247.21M | (m) | $818.55M | $1.27B | (m) |
| 2025-12-31 | (m) | (m) | $41.18M | $246.38M | (m) | $882.22M | $1.42B | (m) |
| 2025-09-30 | (m) | (m) | $17.28M | $158.75M | (m) | $962.53M | $1.44B | (m) |
| 2025-06-30 | (m) | (m) | $14.40M | $159.06M | (m) | $858.13M | $1.23B | (m) |
| 2025-03-31 | (m) | (m) | $12.96M | $92.03M | (m) | $938.22M | $1.26B | (m) |
| 2024-12-31 | (m) | (m) | $11.52M | $93.23M | (m) | $1.08B | $1.40B | (m) |
| 2024-09-30 | (m) | (m) | $11.52M | $93.02M | (m) | $1.01B | $1.44B | (m) |
| 2024-06-30 | (m) | (m) | $11.52M | $92.83M | (m) | $1.06B | $1.52B | (m) |
| 2024-03-31 | (m) | (m) | $11.52M | $56.82M | (m) | $618.96M | $808.08M | (m) |
| 2023-12-31 | (m) | (m) | $10.08M | $58.38M | (m) | $614.82M | $824.32M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $60.88M | (m) | $539.24M | $740.61M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $62.49M | (m) | $565.72M | $779.90M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $64.11M | (m) | $663.96M | $889.82M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $63.81M | (m) | $782.58M | $1.01B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $63.54M | (m) | $867.66M | $1.08B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $62.34M | (m) | $586.03M | $771.72M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $61.16M | (m) | $608.97M | $856.25M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $47.37M | (m) | $471.64M | $841.32M | (m) |
| 2021-09-30 | (m) | (m) | $16.88M | $30.20M | (m) | $477.64M | $827.54M | (m) |
| 2021-06-30 | (m) | (m) | $11.25M | $35.54M | (m) | $350.30M | $564.30M | (m) |
| 2021-03-31 | (m) | (m) | $5.63M | $40.87M | (m) | $425.58M | $577.06M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $46.21M | (m) | $464.06M | $533.80M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $45.92M | (m) | $410.26M | $474.11M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $45.63M | (m) | $213.06M | $232.50M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $45.34M | (m) | $220.71M | $256.58M | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | $45.05M | (m) | $225.11M | $289.81M | (m) |
| 2019-09-30 | (m) | (m) | $0.00 | $44.76M | (m) | $166.04M | $187.39M | (m) |
| 2019-06-30 | (m) | (m) | $0.00 | $44.47M | (m) | $172.87M | $198.22M | (m) |
| 2019-03-31 | (m) | (m) | $6.21M | $36.38M | (m) | $176.62M | $198.61M | (m) |
| 2018-12-31 | (m) | (m) | $2.61M | $39.81M | (m) | $198.73M | $211.18M | (m) |
| 2018-09-30 | (m) | (m) | $3.78M | $38.13M | (m) | $210.31M | $230.28M | (m) |
| 2018-06-30 | (m) | (m) | $1.70M | $30.66M | (m) | $231.94M | $247.24M | (m) |
| 2018-03-31 | (m) | (m) | $0.00 | $31.95M | (m) | $251.45M | $279.93M | (m) |
| 2017-12-31 | (m) | (m) | $0.00 | $31.78M | (m) | $268.89M | $294.81M | (m) |
| 2017-09-30 | (m) | (m) | $9.83M | $20.47M | (m) | $307.57M | $326.31M | (m) |
| 2017-06-30 | (m) | (m) | $7.32M | $22.84M | (m) | $312.05M | $340.63M | (m) |
| 2017-03-31 | (m) | (m) | $4.83M | $25.20M | (m) | $206.56M | $265.37M | (m) |
| 2016-12-31 | (m) | (m) | $2.50M | $27.38M | (m) | $156.25M | $170.14M | (m) |
| 2016-09-30 | (m) | (m) | (m) | $29.74M | (m) | $78.61M | $158.17M | (m) |
| 2016-06-30 | (m) | (m) | (m) | $29.60M | (m) | $90.34M | $106.16M | (m) |
| 2016-03-31 | (m) | (m) | (m) | $29.47M | (m) | $103.42M | $113.22M | (m) |
| 2015-12-31 | (m) | (m) | (m) | $14.64M | (m) | $111.44M | $115.24M | (m) |
| 2014-12-31 | (m) | (m) | (m) | $0.00 | (m) | $83.23M | $132.97M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |